These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 12455034)

  • 1. Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo.
    Scheffer SR; Nave H; Korangy F; Schlote K; Pabst R; Jaffee EM; Manns MP; Greten TF
    Int J Cancer; 2003 Jan; 103(2):205-11. PubMed ID: 12455034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells.
    Chen Z; Moyana T; Saxena A; Warrington R; Jia Z; Xiang J
    Int J Cancer; 2001 Aug; 93(4):539-48. PubMed ID: 11477558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma.
    Goldszmid RS; Idoyaga J; Bravo AI; Steinman R; Mordoh J; Wainstok R
    J Immunol; 2003 Dec; 171(11):5940-7. PubMed ID: 14634105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-21 activates cytotoxic T lymphocytes and natural killer cells to generate antitumor response in mouse renal cell carcinoma.
    Kumano M; Hara I; Furukawa J; Oniki S; Nagai H; Miyake H; Fujisawa M
    J Urol; 2007 Oct; 178(4 Pt 1):1504-9. PubMed ID: 17707061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of tumor-specific CD8+ T Cells after intratumoral Ad5-TRAIL/CpG oligodeoxynucleotide combination therapy.
    VanOosten RL; Griffith TS
    Cancer Res; 2007 Dec; 67(24):11980-90. PubMed ID: 18089829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancing whole-tumor cell vaccination by engaging innate immune system through NY-ESO-1/dendritic cell interactions.
    Xu L; Zheng J; Nguyen DH; Luong QT; Zeng G
    J Immunother; 2013 Oct; 36(8):412-22. PubMed ID: 23994888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concomitant tumor and autoantigen vaccination supports renal cell carcinoma rejection.
    Herbert N; Haferkamp A; Schmitz-Winnenthal HF; Zöller M
    J Immunol; 2010 Jul; 185(2):902-16. PubMed ID: 20548033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
    Wang J; Saffold S; Cao X; Krauss J; Chen W
    J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyper-interleukin-11 novel designer molecular adjuvant targeting gp130 for whole cell cancer vaccines.
    Suchorska WM; Dams-Kozlowska H; Kazimierczak U; Wysocki PJ; Mackiewicz A
    Expert Opin Biol Ther; 2011 Dec; 11(12):1555-67. PubMed ID: 21995459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Booster vaccinations against cancer are critical in prophylactic but detrimental in therapeutic settings.
    Ricupito A; Grioni M; Calcinotto A; Hess Michelini R; Longhi R; Mondino A; Bellone M
    Cancer Res; 2013 Jun; 73(12):3545-54. PubMed ID: 23539449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Murine B16 melanoma vaccination-induced tumor immunity: identification of specific immune cells and functions involved.
    Wu TY; Fleischmann WR
    J Interferon Cytokine Res; 2001 Dec; 21(12):1117-27. PubMed ID: 11798470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A convenient cancer vaccine therapy with in vivo transfer of interleukin 12 expression plasmid using gene gun technology after priming with irradiated carcinoma cells.
    Nishitani MA; Sakai T; Ishii K; Zhang M; Nakano Y; Nitta Y; Miyazaki J; Kanayama HO; Kagawa S; Himeno K
    Cancer Gene Ther; 2002 Feb; 9(2):156-63. PubMed ID: 11857033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CIITA-driven MHC-II positive tumor cells: preventive vaccines and superior generators of antitumor CD4+ T lymphocytes for immunotherapy.
    Frangione V; Mortara L; Castellani P; De Lerma Barbaro A; Accolla RS
    Int J Cancer; 2010 Oct; 127(7):1614-24. PubMed ID: 20091859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trafficking of 'immune' CD4(+)/CD8(+)T-lymphocytes into the RENCA tumour microcirculation in vivo in mice.
    Ali SA; Rees RC; Anderson DQ; Reed MW; Goepel JR; Brown NJ
    Br J Cancer; 2000 Oct; 83(8):1061-8. PubMed ID: 10993655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene-modified tumor vaccine secreting a designer cytokine Hyper-Interleukin-6 is an effective therapy in mice bearing orthotopic renal cell cancer.
    Wysocki PJ; Kazimierczak U; Suchorska W; Kotlarski M; Malicki J; Mackiewicz A
    Cancer Gene Ther; 2010 Jul; 17(7):465-75. PubMed ID: 20168352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
    Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors.
    Liu Y; Saxena A; Zheng C; Carlsen S; Xiang J
    J Gene Med; 2004 Aug; 6(8):857-68. PubMed ID: 15293344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effects of hMIP-1beta gene modification on in vivo tumorigenicity and vaccine efficacy of tumor cells].
    Luo XL; Xie YA; Kuang ZP; Wu JN; Liang AM
    Zhonghua Zhong Liu Za Zhi; 2008 Feb; 30(2):97-102. PubMed ID: 18646689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.